In line with this, it has been reported that cancer patients with PD-L1-expressing CTCs in urothelial carcinoma (18) and melanoma (19) exhibit better treatment outcomes during immune checkpoint inhibitor (ICI) therapy. This evidence concerns the gene CD274 and cancer.